We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

72 hedge funds and large institutions have $41.4M invested in Aldeyra Therapeutics in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 23

6% less funds holding

Funds holding: 7772 (-5)

6.78% less ownership

Funds ownership: 63.33%56.55% (-6.8%)

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

31% less call options, than puts

Call options by funds: $27K | Put options by funds: $39K

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

60% less capital invested

Capital invested by funds: $103M → $41.4M (-$61.4M)

Holders
72
Holders Change
-5
Holders Change %
-6.49%
% of All Funds
1.59%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
22
Reduced
23
Closed
15
Calls
$27K
Puts
$39K
Net Calls
-$12K
Net Calls Change
+$180K

ALDX Hedge Fund Activity: Q1 2020 in Review

72 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2020, worth a combined $41.4M — down 60% from $103M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ALDX and 11 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 22 added.

The largest buyer was Prosight Management, adding an estimated $2.73M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $5.81M sold.

  • 72 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2020, down from 77 in Q4 2019.
  • Funds reported $41.4M of Aldeyra Therapeutics stock for Q1 2020, down 60% quarter-over-quarter.
  • 11 funds opened new Aldeyra Therapeutics positions in Q1 2020 and 15 closed out, a net change of -4 holders.
  • The largest Aldeyra Therapeutics buyer in Q1 2020 was Prosight Management, an estimated $2.73M added.
  • The largest Aldeyra Therapeutics seller in Q1 2020 was Adage Capital Partners, an estimated $5.81M sold.

Based on aggregated 13F filings for Q1 2020.